{"filing":{"accession_number":"0001213900-26-082879","cik":"0001782107","ticker":"ONCO","company_name":"Onconetix, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-28","primary_document":"ea0299510-8k_onconetix.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026082879/ea0299510-8k_onconetix.htm"},"events":[{"id":21774,"run_id":19643,"accession_number":"0001213900-26-082879","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Onconetix entered into a Securities Purchase Agreement to issue 37,812 shares of Series F convertible preferred stock for $30.2 million, with conversion rights into common stock at $0.9767 per share, and established a committed equity facility (ELOC) allowing purchases of up to $750 million in common stock. The unregistered sale relies on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, representing a private investment in public equity (PIPE) transaction that materially dilutes existing shareholders.","company_name":"Onconetix, Inc.","ticker":"ONCO","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21490,"accession_number":"0001213900-26-082879","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Onconetix entered into a Securities Purchase Agreement to issue 37,812 shares of Series F convertible preferred stock for $30.2 million, with conversion rights into common stock at $0.9767 per share. The filing also discloses a committed equity facility (ELOC) allowing purchases of up to $750 million in common stock. These are classic dilutive issuances—unregistered or registered equity sales that increase share count and dilute existing shareholders, material to investors assessing ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:17:11.285563+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21491,"accession_number":"0001213900-26-082879","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of Series F Preferred Stock and Common Stock issuable upon conversion, relying on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D—classic private placement exemptions. The reference to a \"PIPE Investor\" and Securities Purchase Agreement indicates a private investment in public equity, which is a dilutive issuance. The incorporation by reference to Item 1.01 suggests this is part of a broader capital-raising transaction material to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:17:11.285563+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21490,"accession_number":"0001213900-26-082879","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Onconetix entered into a Securities Purchase Agreement to issue 37,812 shares of Series F convertible preferred stock for $30.2 million, with conversion rights into common stock at $0.9767 per share. The filing also discloses a committed equity facility (ELOC) allowing purchases of up to $750 million in common stock. These are classic dilutive issuances—unregistered or registered equity sales that increase share count and dilute existing shareholders, material to investors assessing ownership and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:17:11.285563+00:00","company_name":"Onconetix, Inc.","ticker":"ONCO","filing_date":"2026-07-29"},{"id":21491,"accession_number":"0001213900-26-082879","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of Series F Preferred Stock and Common Stock issuable upon conversion, relying on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D—classic private placement exemptions. The reference to a \"PIPE Investor\" and Securities Purchase Agreement indicates a private investment in public equity, which is a dilutive issuance. The incorporation by reference to Item 1.01 suggests this is part of a broader capital-raising transaction material to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:17:11.285563+00:00","company_name":"Onconetix, Inc.","ticker":"ONCO","filing_date":"2026-07-29"}]}